ClearPoint Neuro (CLPT) Net Income towards Common Stockholders (2011 - 2026)

ClearPoint Neuro (CLPT) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 58.51% year-over-year to -$9.6 million; the trailing twelve-month figure through Mar 2026 stood at -$29.0 million (down 44.21% YoY), and the FY2025 full-year result was -$25.5 million, down 39.75% from the prior year.
• Net Income towards Common Stockholders declined to -$9.6 million in Q1 2026, from -$7.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.1 million in Q1 2024 to a low of -$14.7 million in Q2 2022.
• A 5-year average of -$7.6 million and a median of -$6.0 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 62.47% in 2024 and slumped 64.12% in 2025, its largest moves.
• Tracing CLPT's Net Income towards Common Stockholders over 5 years: stood at -$4.6 million in 2022, then retreated by 5.47% to -$4.9 million in 2023, then increased by 3.49% to -$4.7 million in 2024, then plunged by 64.12% to -$7.8 million in 2025, then fell by 23.2% to -$9.6 million in 2026.
• Business Quant data shows CLPT's Net Income towards Common Stockholders at -$9.6 million in Q1 2026, -$7.8 million in Q4 2025, and -$5.9 million in Q3 2025.